Intellectual disability (ID) is the hallmark of an extremely heterogeneous group of disorders that comprises a wide variety of syndromic and non-syndromic phenotypes. Here, we report on mutations in two aminoacyl-tRNA synthetases that are associated with ID in two unrelated Iranian families. In the first family, we identified a homozygous missense mutation (c.514G>A, p.Asp172Asn) in the cytoplasmic seryl-tRNA synthetase (SARS) gene. The mutation affects the enzymatic core domain of the protein and impairs its enzymatic activity, probably leading to reduced cytoplasmic tRNA Ser concentrations. The mutant protein was predicted to be unstable, which could be substantiated by investigating ectopic mutant SARS in transfected HEK293T cells. In the second family, we found a compound heterozygous genotype of the mitochondrial tryptophanyltRNA synthetase (WARS2) gene, comprising a nonsense mutation (c.325delA, p.Ser109Alafs*15), which very likely entails nonsense-mediated mRNA decay and a missense mutation (c.37T>G, p.Trp13Gly). The latter affects the mitochondrial localization signal of WARS2, causing protein mislocalization. Including AIMP1, which we have recently implicated in the etiology of ID, three genes with a role in tRNA-aminoacylation are now associated with this condition. We therefore suggest that the functional integrity of tRNAs in general is an important factor in the development and maintenance of human cognitive functions.
identified mutations in two aminoacyl-tRNA synthetases (ARSs) in families with ARID. ARSs are essential and ubiquitously expressed enzymes and responsible for ligating amino acids to cognate tRNA molecules (aminoacylation) in mitochondria and in the cytosol. Mutations in at least five mitochondrial ARSs have already been associated with brain-specific phenotypes, and at least four genes encoding cytoplasmic ARS have been implicated in inherited peripheral neuropathy with an axonal pathology (for review see, e.g., Oprescu, Griffin, Beg, & Antonellis, 2016; Wallen & Antonellis, 2013; Yao & Fox, 2013) .
Here, we report on two Iranian families affected by ARID with similar accompanying features (Table 1) . Using homozygosity mapping, next-generation sequencing and Sanger sequencing approaches, we have identified mutations in two different ARS genes. In the first family, homozygosity mapping in combination with subsequent mutation screening revealed a homozygous missense mutation in the Seryl-tRNA Synthetase (SARS) gene (MIM# 607529), which co-segregates with moderate ID, microcephaly, ataxia, speech impairment, and aggressive behavior. The variant affects an amino acid residue that is highly conserved across the animal kingdom and it leads to unstable protein expression in mammalian cells. Moreover, the missense change leads to reduced enzymatic activity in vitro.
In the second family, we found compound DNA-alterations affecting the mitochondrial tryptophanyl-tRNA synthetase (WARS2) gene (MIM# 604733) by whole genome sequencing and could show that both cosegregate with moderate ID, ataxia, speech impairment, microcephaly, and aggressive behavior. The frameshift mutation on the paternal allele 
MATERIALS AND METHODS

Subjects and sampling
The study was approved by the Ethics Committee of the University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. The patients and their families were recruited by the Genetics Research Center at the University of Social Welfare and Rehabilitation Sciences, Tehran, Iran, where genetic counselors obtained informed consent of the parents from both families in writing. The probands were examined by experienced clinical geneticists who assessed their physical and mental status. Blood samples for DNA preparation were collected and genomic DNA was extracted using a standard method.
To exclude chromosomal abnormalities and metabolic disorders, respectively, we performed karyotype analysis by G-banding and tandem mass spectrometry, using filter-dried blood from at least one patient of each nuclear family. Fragile X-syndrome was also excluded.
Linkage analysis and autozygosity mapping
In the case of family 1, linkage analysis and autozygosity mapping were carried out. Genotyping (SNP analysis) was performed using 50k
Genome-Wide Human SNP Array Version 2 (Affymetrix, Santa Clara, CA) (Kennedy et al., 2003) based on previously published protocols (Matsuzaki et al., 2004) for all available individuals from family 1. We used Alohomora 11 software v0.32 (Ruschendorf & Nurnberg, 2005) for SNP array quality controls, as described previously (Garshasbi et al., 2006) . The program Merlin was applied for parametric multipoint linkage analysis consistent with an AR mode of inheritance, a disease allele frequency of 10 −3 and complete penetrance (Abecasis, Cherny, Cookson, & Cardon, 2002) .
Mutation screening and evaluation
Mutation screening for family 1 was performed by PCR analysis and subsequent Sanger sequencing of all exons and exon-intron boundaries of all protein-coding genes within the linkage interval, which was flanked by the heterozygous SNPs rs10494061 and rs1938250 and contained 133 RefSeq genes (human reference genome, assembly GCRh37/hg19), using the DNA of the index patient (V:1). Primers were designed by using Primer3 software (URL: http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) (Rozen & Skaletsky, 2000) . In case of the only plausible candidate gene, SARS, PCR was performed in independent PCR reactions (primers are listed in Supp. Table S1 ). In addition, siblings and parents were also sequenced, when available, to confirm appropriate co-segregation of the allele within the families. Furthermore, ethnically matched unrelated healthy individuals as well as unrelated healthy German individuals were also directly screened for the mutations. Moreover, we used the publically available sequencing databases as well as in-house databases containing more than 400 exomes to further extend the control cohort. The DNA mutation numbering system used is based on the cDNA sequence where +1 is the A of the ATG translation initiation codon in the reference sequence.
In silico prediction of pathogenic effect of the variants identified in this study was performed using Polyphen2 (Adzhubei et al., 2010) , SIFT (Ng & Henikoff, 2001) , Mutation Taster (Schwarz, Rodelsperger, Schuelke, & Seelow, 2010) , and Logit score developed by Hu et al. (2014) .
We employed the PyMOL software (The PyMOL Molecular Graphics System, Version 1.5.0.1 Schrödinger, LLC) to model the protein structures of the mutant SARS based on the wild-type (WT) crystal structures (3VBB) available in the Protein Data Bank PDB (Xu et al., 2012) and performed an in silico analysis to estimate the effect of the mutations on protein stability using Concoord/PBSA (Benedix, Becker, de Groot, Caflisch, & Bockmann, 2009; Potapov, Cohen, & Schreiber, 2009 Family 2 was part of a large study of the molecular basis of ARID and genotyping results of six DNA samples (IV:2, IV:3, V:2, V:7, V:8, V:9) from this family were used for homozygosity mapping and multipoint parametric and non-parametric linkage analysis. We identified three homozygous genomic intervals with LOD scores above 2 (Family M153 (Najmabadi et al., 2011) ). Haplotype construction showed homozygous SNP haplotypes for all affected members within these three intervals. Subsequently, the three homozygous regions were enriched and next generation sequencing was performed but upon filtering no homozygous apparently disease-causing mutation could be identified. More recently, this negative result was confirmed using the medical re-sequencing analysis pipeline Medical
Re-sequencing Analysis Pipeline (MERAP) (Hu et al., 2014) (URL:
https://sourceforge.net/projects/merap). This prompted us to perform whole genome sequencing to search for causative mutations even outside the homozygous regions. Whole genome sequencing was performed in one affected (V:7) by Complete Genomics (Mountain View, CA) as previously described (Drmanac et al., 2010) . The mappable reads sum up to 160G, and the sequence fraction with >10× coverage was 0.976 and with >20× coverage was 0.936. Sequence reads were mapped to the reference genome (human reference genome, assembly GCRh37/hg19). Variants were ranked and prioritized as potential candidates as previously described (Najmabadi et al., 2011) , using an improved version of MERAP (Hu et al., 2014 Table S1 ). Siblings and parents were also sequenced, when available, to confirm co-segregation of the alleles within the family.
Furthermore, ethnically matched unrelated healthy individuals as well as unrelated healthy German individuals were also directly screened for the mutations. DNA mutation numbering system used is based on cDNA sequence where +1 is the A of the ATG translation initiation codon in the reference sequence.
In silico analysis of the putative pathogenic missense change was performed using Project HOPE (URL: http://www.cmbi.ru.nl/hope/).
Prediction of the pathogenic effect of the variant found in this study was performed using various softwares: (Claros & Vincens, 1996) . The output value gives the probability of the protein to be mitochondrial (higher values indicate higher probability).
- TargetP 
Sanger sequencing
Sequencing reactions were prepared using the ABI PRISM Big Dye Table S2 for primer sequences). 
Cell culture and treatment
Generation of whole cell lysates
WT and mutant constructs were transfected into HEK293T and/or COS7 cells. After 24 hr, cells were harvested by centrifugation at 110 × g for 5 min using a Rotanta 46K centrifuge (Hettich, Tuttlingen, Germany) and washed once in 1 × PBS. The pellet was resuspended into lysis buffer (15 mM Tris-HCl, pH 7.5, 48% urea,
8.7% glycerol, 1% SDS, 0.004% bromophenol blue, and 143 mM -mercaptoethanol) and then sonicated 10 sec/two cycles/max power with Sonoplus HD 2070 (Bandelin, Berlin, Germany).
Cell fractionation
EYFP-SARS WT and mutant expression vectors were transfected into HEK293T cells. After 24 hr, cells were harvested by centrifugation at 1,000 rpm for 5 min using a Rotanta 46K centrifuge (Hettich) and washed once in 1 × PBS. The pellet was resuspended in 400 l Cell
Fractionation Lysis Buffer (20 mM Hepes, pH 7.4, 50 mM NaCl, 5 mM MgCl 2 protease inhibitors and 80 g/ml digitonin) and incubated at RT for 10 min, then centrifuged at 956 × g for 10 min (Centrifuge 5417R;
Eppendorf, Hauppauge, NY). The supernatant, which contained the cytosolic fraction, was removed and the pellet was washed twice with Cell Fractionation Lysis Buffer. The pellet, which contained the membrane and nuclear fraction, was resuspended in 150 l of lysis buffer (15 mM Tris-HCl, pH 7.5, 48% urea, 8.7% glycerol, 1% SDS, 0.004% bromophenol blue, and 143 mM -mercaptoethanol) followed by sonication.
Mitochondria isolation
Mitochondria were isolated using the Mitochondria Isolation Kit for Cultured Cells (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer's instructions (option B). Modifications were done as follow:
Step 3, cells were lysed by sonication 5 sec/3 × 2 cycles/max power.
Step 8 and 11, pellets contained nuclei/membranes and mitochondria, respectively, were dissolved in 200 l of lysis buffer (see above) and passed through QiaShredder (Qiagen, Venlo, Netherlands) to reduce viscosity.
Protein concentration was measured by NanoDrop (ND-1000;
Thermo Fisher Scientific, Waltham, MA, USA).
Western blot
Protein extracts (5-25 g) were loaded on 10% to 15% SDS-Gels.
The gels were blotted for 1 hr at 20 V. Membranes were blocked at RT either in 5% BSA or 5% milk in PBST for 1 hr. Incubation with 1st antibody in 5% milk in PBST was done overnight at 4°C. Membranes were incubated with secondary antibodies, diluted in PBST, for 1 hr at room temperature. To detect immunolabeled proteins, we used Western Lightning R ECL, Enhanced Chemiluminescence Substrate (PerkinElmer Inc., Waltham, MA, USA).
Immunocytochemistry
Cells were fixed for 10 min with 4% PFA in PBS, permeabilized in 0.2%
Triton X in PBS for 5 min, and incubated with 4% BSA in PBS for 1 hr at room temperature. They were then incubated overnight with the primary antibodies in the same solution at 4°C, washed three times with PBS and subsequently incubated with secondary antibodies in blocking solution (1 hr), and again washed three times with PBS, dipped in water and mounted with Fluoromount G (Southern Biotech, Birmingham, AL) and 0.5 g DAPI/ml. Images were acquired using a confocal laser-scanning microscope (Laser Scanning Microscope LSM700, Carl Zeiss, Oberkochen, Germany) with a 63×-objective and were analyzed with the Carl Zeiss ZEN 2012 software.
Antibodies
The following antibodies were used: anti-SARS, clone 1H4; mono- no. A21200 and A11037, respectively) and used with a dilution of 1:1,000.
Expression and purification of GST-fusion proteins
The pGEX6P3 vector was used for high-level inducible intracellular expression of SARS WT and mutant proteins in Escherichia coli BL21.
Expression of GST-fusion protein was induced by addition of 1 mm IPTG for 4 hr at 37°C. GST-Protein purification was done using the GST Bulk Kit (GE-Healthcare, Little Chalfont, UK). In summary, cell pellets were dissolved in ice-cold 1 × PBS containing an appropriate amount of complete protease inhibitor tablets, were sonicated using an ultrasonic cell disruptor (Bandelin) at maximum power for 10 sec and two cycles. Afterward, sonicates were centrifuged to remove insoluble material (500g, 4°C, 20 min). Glutathione Sepharose 4B was prepared according to the manufactures instructions. Two microliters of 50% Glutathione Sepharose 4B slurry was added to each 100 ml of lysate sample. The mixture was incubated at 4°C on an overhead shaker overnight. GST-fusion proteins were eluted by addition of 0.5 ml elution buffer per 1 ml of Glutathione Sepharose 4B. Elution was repeated for five to six times and protein concentration was determined by silver staining.
Silver staining was performed using ProteoSilver TM Plus Silver
Stain Kit (Sigma-Aldrich, Munich, Germany) following manufacturer's instructions. For determining protein concentration in gel bands, gels were scanned and analyzed using the ImageQuant software (Molecular Dynamics, GE Healthcare, Little Chalfont, UK).
Buffer exchange was performed with PD-10 Desalting Columns (GE Healthcare, Chicago, IL, USA). The protocol by gravity flow was applied according to the manufacturer's instructions. 
Pyrophosphate release assay
RESULTS
Clinical report of family 1
Family 1 is an Iranian family with Arabian ethnicity. The distantly related parents had nine children, four of them presented with ID;
the pedigree is shown in Figure 1A . All affected children were born at full term after uneventful pregnancies, followed by a normal neonatal period. Testing of cognitive function using the Wechsler Adult Intelligence Scale (WAIS-IV) showed an intelligence quotient (IQ) [40] [41] [42] [43] [44] [45] in the range of moderate ID, speech impairment (slow and slurred speech) and aggressive behavior. In addition, the patients presented with microcephaly, ataxia (unbalanced gait starting at the age of 7-10 years), and muscular weakness (since the age of 6-10). All patients developed tonic-clonic seizures during infancy, which are well controlled by sodium valproate. DNA was extracted from peripheral blood of the patients (III:4, III:9, III:10, III:11), three healthy siblings and their parents, using standard procedures. Clinical descriptions of the patients are summarized in Table 1 .
Clinical report of family 2
Family 2 is an Iranian family from the Semnan province of Iran. The consanguineous healthy parents had nine children, three of them with ID (Fig. 1B) . One affected male (V:6) had died from an infectious dis- 
Linkage analysis and homozygosity mapping in family 1
Parametric linkage analysis in family 1 revealed a single interval of homozygosity on chromosome 1p13.3-p11.2 near the centromere with a significant LOD score above three (Supp. Fig. S1 ). The linkage interval had a size of 12.9 Mb, was flanked by the heterozygous SNPs rs10494061 and rs1938250, and contained 133 protein coding RefSeq genes (human reference genome, assembly GCRh37/hg19). For this study, coding regions including intron-exon boundaries of these genes were amplified by PCR and subsequently sequenced.
Mutation analysis in family 1
In the exonic regions of all 133 genes included in the interval, only two homozygous missense variants co-segregating with the disease in the family 1 were detected in the linkage interval on chromosome 1 (Supp. Fig. S2 ). In the SARS gene a homozygous G to A substitution (chr1: 109773566G>A; NM_006513.3: c.514G>A) ( The mutation affects a highly conserved amino acid (Fig. 1C) and, in line with this, the phyloP score (Pollard, Hubisz, Rosenbloom, & Siepel, 2010 ) was found to be 6.457.
Expression of SARS was determined by RNAseq in different human
brain regions relevant for learning and memory (Supp. Fig. S3 ).
SARS encodes the cytosolic seryl-tRNA synthetase, a protein that contains three domains: an N-terminal tRNA binding arm, an aminoacylation domain and a C-terminal UNE-S domain containing the nuclear localization signal (NLS) ADDIN EN.CITE (Xu et al., 2012) . The amino acid substitution p.Asp172Asn found in family 1 is located in the aminoacylation core domain (Fig. 1C) , in close proximity to the active site (see also Supp. Fig. S4 ).
The amino acid substitution p.Asp172Asn destabilizes SARS
Mutations of single amino acid mutations can significantly change the stability of a protein structure. The p.Asp172 was predicted in silico to be a stabilization center element by the SCide software (Dosztanyi, Magyar, Tusnady, & Simon, 2003) using PDB structure 3VBB and chain F. To understand whether the stability of SARS protein was influenced by the loss of the negative charge at residue 172, protein stability was assessed by MUpro, I-Mutant (ΔΔG = −2.06) and PoPMuSiC (ΔΔG = 0.62 kcal/mol). All three tools predicted a moderate decrease in protein stability upon mutation. Even more important, in silico energy calculations with the Concoord/PBSA method (Benedix et al., 2009) , which calculates stability changes upon mutation confirmed a decrease in stability (ΔΔG = −1.06).
To gain insights into the structural consequences of the p.Asp172Asn mutation, structure-based in silico modeling of the p.Asp172Asn amino acid substitution was performed using the crystal-structure 3VBB of human SARS (Xu et al., 2012) .
p.Asp172 is located in the aminoacylation domain, in close proximity to p.His170 (Supp. Fig. S3A ). Xu et al. (2012) have also shown that residues p.His170 and p.Phe316 form hydrophobic interactions to stabilize the 10-11 hairpin. This hairpin belongs to the seven-stranded antiparallel -sheet ( 1-9-10-11-13-8-7), which is the central core of the aminoacylation domain (Xu et al., 2012) .
Aspartic acid and asparagine are geometrically similar and protein modeling showed that p.Asp172 faces away from the active site (Supp. Fig. S4A ), therefore p.Asp172Asn has probably no structure-based influence on the catalytic core domain. However, p.Asp172 could affect aminoacylation activity in an indirect manner as it provides a negative charge. This negative charge is lost in SARS p.Asp172Asn. Furthermore, the mutation site p.Asp172 is located directly adjacent to the N-terminus of the UNE-S domain, which contains the NLS (Supp. 
Expression analysis of SARS p.Asp172Asn in mammalian cells
To test the hypothesis that p.Asp172Asn might influence the localization pattern of SARS, we cloned WT and mutant SARS in frame with C-terminal EYFP tag. In parallel, subcellular localization of endogenous SARS was analyzed using a monoclonal SARS antibody. Confocal microscopy revealed a similar cytoplasmic localization of endogenous and ectopic SARS proteins in all cell lines tested (data not shown) which is in agreement with previous studies (Xu et al., 2012) .
Subsequently, we transfected HEK293T cells with EYFP-SARS WT
and p.Asp172Asn expression vectors for 24 hr and transfection efficiency was determined in parallel by counting transfected cells by fluorescence microscopy. Transfections rates were 40.8 ± 3.2% for SARS WT and 39.8 ± 1.1% for SARS p.Asp172Asn, respectively. Data to evaluate transfection efficiency were derived from three independent transfections.
After transfection, cells were harvested and total protein lysate as well as cytosolic and nuclear protein fractions were extracted.
Expression of ectopic WT and mutant SARS proteins were analyzed by
Western blotting using monoclonal anti-GFP antibody ( Fig. 2A upper panel). The same membranes were then hybridized with anti-tubulin ( Fig. 2A middle panel) and anti-lamin antibodies ( Fig. 2A bottom panel) .
Tubulin and lamin were used as control for cell fractionation and normalization.
Quantification of six independent experiments revealed that expression of p.Asp172Asn was significantly reduced as compared with the WT in whole cell extracts as well as in the cytosolic fraction (P < 0.005) (Fig. 2B ). In the nuclear fraction, signals were very weak and differences did not reach a level of statistical significance.
F I G U R E 2 A:
Whole cell lysate (WCL), cytoplasmic (CF), and nuclear (NF) fractions from HEK293T cells transfected either with EYFP-SARS wild-type (WT) or mutant (p.Asp172Asn) were run on SDS-PAGE. The gel was blotted and probed with -GFP antibody. The blot was subsequently probed with -tubulin and -lamin antibodies as loading controls for cytosolic and nuclear fractions, respectively. B: Quantification of EYFP-SARS WT or mutant (p.Asp172Asn) expression in HEK293T cells. Quantification of bands from Western blots was performed using ImageQuant software (Molecular Dynamics). Tubulin was used to normalize SARS protein expression. On the left, histogram showing a statistically highly significant reduction of SARS p.Asp172Asn expression compared with the expression of SARS WT in total cell lysate from HEK293T cells (n = 6; t-test (two-tailed, homoscedastic): ***P < 0.001, SARS p.Asp172NAsn expression is reduced to 67% of SARS WT expression. In the middle, histogram showing significant reduction of mutant SARS in the cytosolic fraction as compared with the WT SARS (n = 6; t test (two-tailed, homoscedastic): ***, P < 0.001). SARS p.Asp172Asn expression is reduced to about 60% of SARS WT expression. C: Results of pyrophosphate release assay. During the first step of the aminoacylation reaction, serine-adenylate is formed and pyrophosphate is released. Equal amounts of recombinant SARS WT and mutant (p. Asp172Asn and p.Thr429Ala) proteins were used to assay the first step of aminoacylation. The pyrophosphate released (nmol P) during serine activation was measured in a colorimetric reaction using BIOMOL GREEN Reagent TM . At 60 min p.Asp172Asn SARS (n = 4; red) shows highly statistically significant reduction of
Impaired serine-activation of the SARS p.Asp172Asn enzyme
In silico modeling of SARS revealed that p.Asp172 maps close to the active site of the protein (Supp. Fig. S3A ) in the tRNA-synthetase class II core domain (Fig. 1C) . Although it is facing away from the active site, p.Asp172 might influence SARS aminoacylation activity because of its negative charge, which is lost upon mutation (p.Asp172Asn). Aminoacylation is performed by ARSs in a two-step reaction: first, an ARS binds an amino acid and ATP to form an aminoacyladenylate (AA-AMP). At the same time, pyrophosphate (P 2 O 7 4− , PPi) is released. In the second step, the amino acid is transferred onto the 3 ′ terminal adenosine of the tRNA that is to be charged and subsequently the charged tRNA and the AMP molecule are released from the enzyme (Schimmel & Soll, 1979) . To understand whether mutant SARS is still able to perform the first step of aminoacylation, we established a pyrophosphate release assay. As prerequisite SARS WT and mutant (p.Asp172Asn and p.Thr429Ala) cDNAs were cloned into pGEX6P3. SARS protein with a p.Thr429Ala mutation is unable to bind serine as this alteration affects a serine binding site (Fig. 1C ) and lacks enzymatic activity (Fukui, Hanaoka, & Kawahara, 2009 ). This protein was used as a negative control during the aminoacylation test.
The purified GST protein was used as an additional negative control. For each protein, activity measurements were performed at three different time points (0, 60, and 90 min) (Fig. 2C) . The pyrophosphate release of the WT SARS reached a maximum at 60 min, and after 90 min of incubation the enzyme still released approximately two thirds of the maximal amount of pyrophosphate as a by-product of serine activation. Firstly, this reduced rate of pyrophosphate production can be explained by entering of AMP into the back reaction of amino acid activation. It was shown by Rapaport, Remy, Kleinkauf, Vater, and Zamecnik (1987) that this mechanism is an inherent part of the catalytic activities of ARSs and could prevent the buildup of enzymebound or free aminoacyl adenylates. Secondly, substrate inhibition might cause the decrease in aminoacylation activity because seryladenylate canremain bound to the SARS enzyme. During aminoacylation of E. coli alanyl-tRNA synthetase (AARS), the alanyl-adenylate product remains bound tightly to the enzyme and is only turnedover when tRNA Ala is present in the reaction. In addition, pyrophosphate generated in the adenylation step substantially inhibits the initial rate of aminoacylation of tRNA Ala in a dose dependent manner.
The degree to which pyrophosphate inhibits a given reaction depends, inter alia, on the extent to which the reaction has progressed. However, the mechanism of this inhibition still needs to be established (Wolfson & Uhlenbeck, 2002) . Remarkably, a highly significant loss of serine-activation was observed for the SARS p.Asp172Asn mutant. At 60 min, GST-SARS p.Asp172Asn released only 28% pyrophosphate as compared with the GST-SARS WT enzyme and even after 90 min of pyrophosphate release as compared with the WT SARS. The catalytically inactive p.Thr429Ala SARS (blue) released no pyrophosphate (n = 6). Data were normalized to individual background activity. ***:
incubation GST-SARS p.Asp172Asn still produced 51% less pyrophosphate than the WT enzyme at 60 min. Consistent with previous findings (Xu et al., 2012) , the GST-SARS p.Thr429Ala was inactive during the assay (Fig. 2C) . As expected, the GST protein did not show any pyrophosphate release (data not shown).
Compound heterozygous WARS2 mutation in family 2
As a result of whole genome sequencing, we found a compound heterozygous genotype of the WARS2 gene in the affected individuals of family 2 (Fig. 1B and D) .
WARS2 is a nucleus-encoded tryptophanyl-tRNA synthetase, which is imported into mitochondria. The protein contains an Nterminal mitochondrial targeting signal, and a C-terminal domain with tryptophan-tRNA ligase activity (Fig. 1D) . Furthermore, it is probably able to load tRNA(Sec) with serine, which would result in a misacylated tRNA, L-seryl-tRNA(Sec) that can be further converted into selenocysteinyl-tRNA(Sec). Expression of WARS2 was evaluated by RNAseq in different human brain regions relevant for learning and memory (Supp. Fig. S5 ).
The WARS2 genotype we observed in the affected individuals comprises a frameshift mutation on the paternal allele and a missense change on the maternal allele. The mutations cosegregated with the disease in the family (Supp. Fig. S6 and Supp. Table S3 ).
Both were submitted to the public Leiden Open Variation Database 3.0 (http://www.lovd.nl/). The frameshift mutation in exon 2 of the gene (chr1:119618996delA, NM_015836.3: c.325delA, NP_056651:
p.Ser109Alafs*15) leads to a premature stop codon and, given its location relative to the terminal exon 6, is most likely to cause nonsense mediated decay (NMD) (Fig. 1D ), resulting in a complete loss of a functional gene product from this allele. The change was not found in the various control panels used (see p.14)
The second change (chr1:119683231A>C, NM_015836.3: c.37T>G) (Fig. 1D ) was also absent in controls (see p.14) and is 
Impaired mitochondrial localization of the WARS2 p.Trp13Gly protein
To experimentally test the hypothesis that the p.Trp13Gly change is functionally relevant, we first performed immunofluorescence microscopy experiments, which revealed that WARS2-EYFP and p.Trp13Gly-WARS2-EYFP were present in the cytoplasm of COS7 cells, in dot-like structures. To investigate whether these punctuated structures represent mitochondria, we treated live cells with
MitoTracker, a red-fluorescent dye that stains mitochondria. Furthermore, its accumulation is dependent upon mitochondrial membrane potential (Chazotte, 2011) . Upon treatment, most WARS2-WTpositive granules overlapped with the mitochondria staining, thus confirming previous findings (Jorgensen, Sogaard, Rossing, Martensen, & Justesen, 2000) , whereas a partial reduction in the overlapping signal was observed for the p.Trp13Gly mutant (Fig. 3A) . This result was further substantiated by the results of a co-staining experiment with the mitochondrial marker HSP60 (Fig. 3B) .
To confirm the localization of WARS2 to the mitochondria and to further evaluate if p.Trp13Gly has a negative impact in this context, we performed subcellular fractionation to isolate mitochondria from HEK293T cells transiently expressing WARS2-EYFP and p.Trp13Gly-WARS2-EYFP. Protein lysates from mitochondrial and cytosolic fractions were then submitted to SDS gel and Western blot analysis. This revealed that both WT and mutant WARS2 were enriched in the mitochondrial fraction. A specific antibody against PHB1, a mitochondrial marker, was used to confirm the quality of the subcellular fractionation (Supp. Fig. S7 and Fig. 4 ). To determine if the p.Trp13Gly change, which affects the mitochondrial SP in WARS2, could impair the protein translocation to the mitochondria, we quantified the amount of WT and mutant protein in the isolated mitochondrial fraction, using a panel of mitochondria specific proteins for normalization. This analysis revealed that the amount of p.Trp13Gly-WARS2 in the mitochondria was significantly reduced as compared with the WT protein ( Fig. 4A-E) . Western blot analysis of total protein lysates extracted in parallel, showed no significant difference between total amount of WARS2 WT and p.Trp13Gly-WARS2 ( Fig. 4F and G) . The transfection efficiency was determined by counting transfected cells by fluorescence microscopy. Transfections rates were 42.8 ± 2.2% for WARS2 WT and 40.8 ± 1.3% for WARS2 p.Trp13Gly, respectively. Data were derived from three independent transfections. Interestingly, by immunofluorescence analysis, using a specific antibody against SDHA, a catalytic subunit of succinate-ubiquinone oxidoreductase, and part of the mitochondrial respiratory chain, we observed a marked decrease of SDHA signal (Supp. Fig. S8 ) in cells overexpressing WT WARS2 compared with cells overexpressing the mutant protein and control cells.
F I G U R E 3
Confocal immunofluorescence microscopy showing the mitochondrial localization of EYFP-WARS2 wild-type (WT) and mutant (p.Trp13Gly) in COS7 cells. Transfection rates were 42.8 ± 2.2% for WARS2 WT and 40.8 ± 1.3% for WARS2 p.Trp13Gly, respectively (based on three independent transfections). The green signal corresponds to WARS2 staining, the red signal correspond to MitoTracker, a fluorescent dye that stains mitochondria whereas the blue corresponds to nuclear DAPI staining. Scale bars = 10 M. B: Subcellular co-localization of EYFP-WARS2 WT and mutant (p.Trp13Gly) (green signal) with the mitochondrial marker HSP60 (red signal). Blue signal corresponds to nuclear DAPI staining. Scale bars: 10 M Western blot analysis performed on the mitochondrial fraction confirmed this observation: the amount of SDHA was significantly reduced upon WT WARS2 overexpression as compared with mutant WARS2 (Fig. 4A and H) .
DISCUSSION
In this report, we describe putatively ID causing mutations in SARS and WARS2 in families with closely overlapping additional clinical features including moderate ID, speech impairment, seizures, ataxia, and muscular weakness. The occurrence of ataxia is consistent with previous reports that implicate ARSs in the etiology of this particular feature (see e.g. (Lee et al., 2006) ). Moreover, muscular weakness was repeatedly observed in the context of tRNA-related disorders in general or ARS-related conditions in particular, for example, Charcot-MarieTooth (CMT) disease (MIM# 607731) and others (see e.g. (Abbott, Francklyn, & Robey-Bond, 2014; Bansagi et al., 2015; Irobi, De Jonghe, & Timmerman, 2004; McLaughlin et al., 2012) , which also supports our conclusion that the phenotype in our families is caused by the DNAalterations we report here.
The gene products of both genes are involved in tRNAaminoacylation and we could confirm that both are well expressed in tissues relevant for memory and learning in the mature brain. Together with AIMP1, which we have recently found to be implicated in ID without neurodegeneration (Iqbal et al., 2016) , there are now at least three genes with a role in tRNA-aminoacylation that are apparently relevant for human cognition.
The SARS gene product catalyzes the attachment of serine to tRNA(Ser). Moreover it is likely able to charge tRNA(Sec) with serine, resulting in the misacylated tRNA L-seryl-tRNA(Sec), which can be further converted into selenocysteinyl-tRNA(Sec). We found that the p.Asp172Asn alteration we identified leads to impaired serineactivation of the SARS enzyme.
In the second family, whole genome sequencing revealed a compound heterozygous genotype in affected individuals, consisting of a deleterious frame-shift mutation and a missense change (p.Trp13Gly)
in the mitochondrial tryptophanyl-tRNA synthetase encoding WARS2.
We could show that the latter has a putative effect on structure and et al., 2011) . This is interesting because the disease causing potential of such alterations might in many cases not be identified by the presently available prediction algorithms, so that in NGS-based mutation screening studies such polymorphisms are probably still being filtered out.
A recently generated targeted Wars2 rat model supports our hypothesis: While, like in uncharacterized Wars2knockout mice (URL: http://www.informatics.jax.org/), the Wars2-deficient allele is embryonically lethal in a homozygous state (Wars2 −/− ), heterozygous animals (Wars2 −/+ ) appear normal. Moreover, it has been shown that animals heterozygous (Wars2 −/L53F ) for the knockout allele and Wars2 p.Leu53Phe, a common variant in rat strains that is associated with a 40% reduction in Wars2 activity, revealed diminished cardiac angiogenesis and reduced coronary flow as compared with animals with compound heterozygosity for the WT allele and the p.Leu53Phe allele (Wars2 +/L53F ) (Wang et al., 2016) . This suggests that Wars2 −/L53 represents a compound hypomorph similar to the situation observed in our patients.
Functionally the mutations we found in SARS and WARS2 might lead to a reduced amount of charged tRNA available for translation at the ribosomes, which in turn could lead to a reduced translation rate, especially of those proteins that contain high amounts of serine, selenocysteine or tryptophan, respectively. Selenocysteine for example is an essential component of the 25 selenoproteins encoded in the human genome (Lu & Holmgren, 2009) . Selenoproteins are involved in protein folding, degradation of misfolded membrane proteins, and control of cellular calcium homeostasis (Andersen, 2004) . Interestingly, deletion of selenoprotein P (Sepp1) in mice produces both neuronal and axonal degeneration as well as potentially reversible neurite changes in the developing brain (Caito et al., 2011) . Neuron-specific ablation of selenoprotein expression causes a neurodevelopmental and neurodegenerative phenotype in mice, affecting the cerebral cortex and the hippocampus, particularly the parvalbumin (PV)-positive interneuron population (Wirth et al., 2010) . Moreover, loss of PV neurons is associated with some neuropsychiatric disorders, for example, autism spectrum disorders (Sgado et al., 2013) .
Specifically with respect to SARS p.Asp172Asn, our overexpression experiments, which we carried out in HEK293T cells, because of their high transfection efficiency and because they are commonly used to assess an impairment of localization in the mitochondria, showed that in comparison to the ectopic WT protein the level of ectopic p.Asp172Asn was significantly reduced in whole cell extracts as well as in the cytosolic fraction. As transfection rates for both were similar this is most likely due to the mutation, suggesting reduced protein stability of mutant SARS, which is also in line with our 3D modeling results. Intriguingly, the observed amounts of WT and mutant SARS in the nuclear fraction were similar, indicating that while the mutation seems to affect the overall stability and function of the SARS gene product, the nuclear transport properties seem to be unaffected. Loss of SARS or severe impairment of SARS function might slow down overall translation rates during cellular processes that depend on fast and reliable protein translation (e.g., in axonal growth cones; reviewed by Jung & Holt, 2011; Swanger & Bassell, 2011) phenotype that does not only comprise peripheral neuropathy but also self-abusive behavior and developmental delay. Finally, it is also noteworthy that in the presence of a tryptophanyl-tRNA deficiency, neurodegenerative symptoms can be induced by tryptamine. Tryptamine induces axonopathy and mitochondriopathy mimicking neurodegenerative diseases via tryptophanyl-tRNA deficiency (Paley, Perry, & Sokolova, 2013) .
Regarding WARS2, it is interesting to note that mutations in human mitochondrial ARSs are associated with various neurodegenerative diseases and that all other mitochondrial ARSs, were already found to be subject to pathology-related mutations (Diodato, Ghezzi, & Tiranti, 2014; Hallmann et al., 2014; Konovalova & Tyynismaa, 2013; Schwartzentruber et al., 2014; Schwenzer, Zoll, Florentz, & Sissler, 2014; Sofou et al., 2015; Suzuki, Nagao, & Suzuki, 2011) . Mitochondrial protein synthesis is central to the mitochondrial oxidative phosphorylation system (OXPHOS). Why clinical consequences of mutations in essential genes are restricted to the brain is still unclear, however, it has been suggested before that, given the fundamental function of mitochondrial ARSs, a loss-of-function is incompatible with life but that low enzyme activity may be sufficient to allow uterine development yet still result in specific disorders during postnatal life (Konovalova & Tyynismaa, 2013) . The high demand of energy for the maintenance of brain functions makes the central nervous system particularly sensitive to disturbances in the (mitochondrial) OXPHOS and it is conceivable that cognitive functions, being the last to develop during evolution, suffer first from imbalances in the energy supply system. When present at crucial neurodevelopmental stages such disturbances could result in permanent damage, while other tissues or functions might not be affected, the residual WARS2 activity being sufficient to cover the demand in these cases.
Furthermore, synapses might be particularly vulnerable to imbalances in the cell-or energy metabolism caused by either cytoplasmic or mitochondrial class I and class II ARSs (Najmabadi et al., 2011) . As reviewed by Valnegri, Sala, and Passafaro (2012) , more than 50% of ID-related proteins are enriched in synaptic compartments and may be involved in synaptic plasticity, synapse formation and cytoskeleton rearrangement (see also Ropers & Hamel, 2005) . Histological data, which also show a correlation between the severity of ID and the severity of dendritic spine malformations (Valnegri et al., 2012) , further corroborate the hypothesis that some features of ID are caused by alterations in synaptic functions. Thus, for further experiments aimed at investigating a possible effect on synapse morphology neuronal cell lines or primary neurons might be advantageous.
Interestingly, SARS and WARS2 also seem to interact directly in some cases, as an analysis using the STRING (http://string-db.org, (Szklarczyk et al., 2015) , last accessed 07/2016) database showed. Still, in which way this could be relevant in the context of the human brain remains to be investigated.
With SARS, WARS2, and the previously implicated AIMP1, a noncatalytic component of the multi-tRNA synthetase complex and modulator of aminoacylation activity of cytoplasmic arginyl-tRNA synthase RRS (Iqbal et al., 2016) there are now at least three genes involved in tRNA-aminoacylation that play a role in the pathology of hereditary cognitive disorders. In this context, it is worthwhile mentioning that various tRNA-modifiers were already found to play a role in the etiology of ID as well (see Balke, Kuss, & Muller, 2015 for review).
It therefore seems that tRNA-modification and -aminoacylation are emerging to be among the more prominent pathways contributing to the molecular background of human cognitive disorders and in conclusion, we would like to present the notion that not only a full but also a fully functional complement of tRNAs is vital for the development and maintenance of higher brain functions.
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